Results 141 to 150 of about 202,164 (266)

Clinical Validation of a QSP Model for ISB 2001, a Trispecific T Cell Engager to Support Optimal FIH Study Design in RRMM Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
ISB 2001 is a trispecific antibody that binds to two tumor‐associated antigens (TAA), CD38 and BCMA, and crosslinks to CD3 on T cells resulting in T cell‐mediated cytotoxicity of tumor cells expressing these TAAs. ISB 2001 is currently being tested in relapsed and/or refractory multiple myeloma (RRMM) patients in the first‐in‐human (FIH) TRIgnite‐1 ...
Vinu Chandralayam Ayyappa Menon   +11 more
wiley   +1 more source

Harmonization of IGF1 immunoassays towards a higher-order LC-MS/MS reference anchor. [PDF]

open access: yesEndocr Connect
Lentjes EGWM   +5 more
europepmc   +1 more source

Prediction of Acute Liver Injury Trajectory in Patients Following Acetaminophen Overdose: A Multibiomarker Machine Learning Proof‐of‐Concept Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Clinical translation of novel therapies can be hindered by heterogeneity‐driven sample size inflation in late‐stage trials. In acetaminophen‐induced liver injury (APAP DILI), many patients recover spontaneously, diluting investigational drug efficacy signals.
Chris Humphries   +8 more
wiley   +1 more source

Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The minimal anticipated biological effect level (MABEL) approach to first‐in‐human (FIH) dose calculation can lead to long dose‐escalation periods before observing clinical activity. We used a novel ex vivo MABEL approach to calculate the FIH starting dose for forimtamig, a T‐cell bispecific antibody under investigation for the treatment of relapsed ...
Thomas E. Kraft   +16 more
wiley   +1 more source

Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice. [PDF]

open access: yesJ Prev Alzheimers Dis
Hortsch S   +9 more
europepmc   +1 more source

Detection of the GH Analogue Redalsomatropin Alfa in Sports Drug Testing: Immunological Approaches and LC‐HRMS/MS

open access: yesDrug Testing and Analysis, EarlyView.
After evaluating the compatibility of the GH analogue redalsomatropin alfa with approved doping control immunoassays for rhGH, it was implemented into the existing detection method for somatrogon employing affinity purification with GHR‐Fc‐conjugated magnetic beads, tryptic digestion, and LC‐HRMS/MS to allow for a specific and sensitive detection ...
Katja Walpurgis   +6 more
wiley   +1 more source

Peptide Aptamer-Enabled Nanoplasmonic Digital Immunoassay for Ultrasensitive Cytokine Sensing in Early Inflammation and Immune Modulation. [PDF]

open access: yesACS Sens
Wu S   +11 more
europepmc   +1 more source

In Vitro Metabolism of Δ8‐, Δ9‐, and Δ10‐THC in Human Hepatocytes: Distinct Δ10‐THC Biotransformation and Implications for Drug Testing

open access: yesDrug Testing and Analysis, EarlyView.
Δ8‐THC and Δ9‐THC showed comparable metabolic profiles. In contrast, Δ10‐THC underwent extensive glucuronidation and hydroxylation, with only minor formation of a carboxy metabolite, indicating a markedly different metabolic pathway. These differences may increase the risk of misidentification and misinterpretation in cannabis drug testing.
Robert Kronstrand   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy